Jaguar8 commented on a stock · Nov 16, 2024 08:04

NEWS

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics (Nasdaq: TARA) announced upcoming presentation of interim data from its Phase 2 ADVANCED-2 trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC) at the Society of Urologic Oncology Annual Meeting. The presentation will include safety data and new efficacy results from approximately 20 enrolled patients. The ADVANCED-2 trial is an open-label study evaluating intravesical TARA-002 in NMIBC patients with carcinoma in situ who are BCG-unresponsive or BCG-naïve. The BCG-Unresponsive cohort (n≈100) is designed to be registrational in alignment with FDA's 2024 guidance, while the BCG-Naïve cohort targets 27 patients.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

16K Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8177

Followers

Following

93K

Visitors